In contrast, PAD4 has been shown to promote progression in triple-negative breast cancer (TNBC), a tumor lacking estrogen receptor, progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2) expression. Here, PGR is linked to triple-negative breast carcinoma.